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Short Synthesis of Idraparinux by Applying a 2-O-Methyl-4,6-O-
arylmethylene Thioidoside as a 1,2-trans-α-Selective Glycosyl
Donor
Fruzsina Demeter,[a] Fanni Veres,[a] Mihály Herczeg*[a,b] and Anikó Borbás*[a]
Abstract: The fully O-sulfated, O-methylated, heparin-related6
anticoagulant pentasaccharide idraparinux was prepared by a
new synthetic pathway in 38 steps using D-glucose and methyl
α-D-glucopyranoside as starting materials, with 23 steps for the
longest linear route. The L-idose-containing GH fragment was
obtained by a short and straightforward synthesis whereby a11
4,6-cyclic-acetal-protected L-idosyl thioglycoside bearing a C2-
Introduction
Heparin polysaccharide and its smaller fragments are invaluable21
drugs in the prevention and treatment of thromboembolic dis-
eases owing to their anticoagulant properties.[1] Heparin binds
to and activates antithrombin which, in turn, inhibits blood co-
agulation factors IIa and Xa.[2] Characterization of the shortest
heparin sequence able to activate antithrombin, the DEFGH26
pentasaccharide 1, along with SAR studies led to the synthetic
antithrombotic drug fondaparinux (Arixtra, 2), possessing selec-
tive factor Xa inhibitory activity by means of activation of anti-
thrombin[3] (Figure 1). The lengthy and demanding synthesis of
fondaparinux[4] spurred research to design simplified analogues31
that are easier to prepare. The replacement of glucosamine by
glucose units and the introduction of methyl ethers to hydrox-
yls on non-crucial positions resulted in the discovery of non-
glycosaminoglycan derivatives such as idraparinux (3)[3,5] which
is an extremely potent heparinoid antithrombotic. Idraparinux36
binds to antithrombin significantly stronger than fondaparinux
through the additional interaction of the extra sulfate group of
the H glucose unit as well as through hydrophobic interactions.
The potency of idraparinux is associated with its long half-life
which allows a convenient once-a-week administration in hu-41
mans. However, in the lack of neutralizing agent, the long elimi-
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nonparticipating group was used as the α-selective glycosyl do-
nor. The novel L-idose donor was prepared with high chemo-
and stereoselectivity by hydroboration–oxidation-based C5 epi-
merization starting from an orthogonally protected α-thio- 16
glucoside. The assembly of the pentasaccharide backbone was
achieved by an F+GH and DE+FGH coupling sequence with full
stereoselectivity in each glycosylation step.
nation half-life proved to be a double-edged sword, and the
development of idraparinux was stopped due to major bleed-
ing events during treatment for more than six months.[6]
Figure 1. Structure of the AT-binding pentasaccharide domain of heparin (1)
and the synthetic anticoagulant pentasaccharides fondaparinux (2) and idra-
parinux (3).
Recently, new antidotes have emerged in the anticoagulant 46
therapy.[7] Andexanet alfa, a recombinant protein designed as
a specific reversal agent against both direct and indirect factor
Xa inhibitors, was approved by FDA in 2018.[8] Aripazine (cira-
parantag), a synthetic small cationic compound is another, clini-
cally investigated reversal agent with promising activity against 51
heparinoid anticoagulants.[9] These new results might attract
renewed interest toward idraparinux.
Despite the simplified structure, the synthesis of idraparinux
still poses challenges like the efficient synthesis of the L-idosyl
building block as well as the introduction of methyl ethers onto 56
the uronic acid residues which are prone to suffer -elimination
under basic conditions of the etherification.
In most syntheses, orthogonally protected 2-O-acyl L-idopyr-
anose or L-iduronic acid building block is prepared from D-gluc-
ose via various lengthy procedures[10] and used as a C2-partici- 61
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Scheme 1. Synthetic strategies toward the GH fragment of idraparinux.
pating glycosyl donor (Scheme 1, A). The 2-O-acyl group en-
sures the required 1,2-trans stereoselectivity upon glycosylation,
however, its change into methyl ether further lengthens the
synthesis at an oligosaccharide level.[5,11–14] Recently, Lopatkie-
wicz and co-workers established a nonglycosylating chemical66
strategy for the synthesis of idraparinux in which the GH and
EF disaccharide units were prepared from the same cellobiose
(Scheme 1, B).[15] They introduced the needed methyl ethers at
an early stage of the synthesis and the functionalized cellobiose
was transformed to the GH unit via epimerization of C5′ by an71
elimination-addition sequence. The synthesis of fully protected
idraparinux was significantly shortened and improved by this
imaginative approach which still has weaknesses such as the
low efficacy of the C5′ epimerization step as well as the low
stereoselectivity during conversion of the 1,6-anhydro ring of76
unit H into methyl α-glycoside.
Very recently, we published a straightforward new synthesis
of L-idosyl glycosyl donors starting from orthogonally protected
α-thioglucosides.[16] The key steps include C5 epimerization by
hydroboration/oxidation of the corresponding 5-enopyrano-81
sides followed by a 4,6-O-acetal formation of the obtained L-
idosides. We demonstrated in model glycosylations of a GlcNAc
acceptor that the 4,6-arylmethylene acetal ensures full 1,2-
trans-α-selectivity in the absence of a participating group at C2
position. On the basis of these results we envisioned a signifi-86
cantly shortened route to idraparinux by applying a 2,3-di-O-
methylated L-idosyl donor for the synthesis of the GH fragment.
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Results and Discussion
We have developed an efficient synthetic strategy for idrapar-
inux[14] and related pentasaccharides[17,18] which was based on 91
the coupling of an FGH acceptor and a DE donor, both contain-
ing a non-oxidized precursor of the hexuronic acid unit, and
formation of the uronic acids was performed in one step at
the pentasaccharide level. While keeping this post-glycosylation
oxidation strategy,[19] we devised a significantly shortened syn- 96
thesis for the GH building block by utilizing a new, non-partici-
pating L-idosyl glycosyl donor which is readily available from a
suitably protected α-thioglucoside by our recent method.[16]
The synthesis of the starting α-thioglucoside 4[20] was ac-
complished by stereoselective introduction of the ethylthio 101
aglycon to 2-acetoxy-D-glucal by photoinduced hydrothiol-
ation[21,22] followed by deacetylation and 4,6-O-(2-naphthyl)-
methylenation. The methyl ether functions of the final product
were introduced into positions 2 and 3 at this early stage of
synthesis to give 5 in 92 % yield. Next, the regioselective ring 106
opening of the 4,6-O-(2-naphthyl)methylene acetal using the
LiAlH4/AlCl3 reagent combination in a 3:1 ratio[23] resulted in
compound 6 in an excellent 90 % yield. Subsequent substitu-
tion of the 6-OH group with iodine gave 7 in 84 % yield. It is
worth mentioning that each compound of this reaction se- 111
quence was obtained in crystalline form (Scheme 2).
Conversion of 7 into the L-idoside derivative 8 was carried
out by the well-established C5-epimerization method including
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Scheme 2. Synthesis of the 6-deoxy-6-iodo-α-thioglucoside derivative 7.
NaH-mediated elimination, hydroboration using BH3·THF and
oxidation with H2O2 under basic conditions.[24,25]116
While this reaction sequence had proceeded both in high
yield and high stereoselectivity starting from 2,3-di-O-benzyl α-
thioglucosides,[16] upon dehydrohalogenation of the 2,3-di-O-
methylated 7 with sodium hydride a number of byproducts
were observed by TLC and, after hydroboration/oxidation, the121
expected L-idose derivative 8 was only formed in low 41 % yield
(Scheme 3, Route A). Thus, we attempted to produce the 5,6-
unsaturated 7a derivative by another method using silver fluor-
ide in dry pyridine (Scheme 3, Route B). To our great satisfac-
tion, the AgF-mediated elimination provided cleanly the 6-de-126
oxy-α-D-xylo-hex-5-enopyranoside 7a which was subjected di-
rectly to hydroboration-oxidation to produce the desired L-
idose derivative 8 in a good yield of 66 % over three steps (87 %
per step). As we expected, the α-anomeric configuration of 7a
ensured the required high L-ido selectivity in the hydroboration131
step and the D-gluco epimer by-product 6 was formed only in a
negligible amount. Moreover, the oxidation occurred with high
chemoselectivity indicated by the small extent of overoxidized
Scheme 3. The elimination and epimerization reactions of compound 7.
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by-product 9. (The structure of 6 and 9 was identified on the
basis of the MS data and NMR spectra of their inseparable mix- 136
ture.) The observed high stereo- and chemoselectivity of the
hydroboration/oxidation of the α-thioglycoside is in line with
our previous results.[16] A third by-product, the 6-fluoro deriva-
tive (10) of the initial glucose compound was also isolated from
the reaction mixture in an 11 % yield. It must have been formed 141
during the elimination reaction, but could not be distinguished
by TLC from the 5,6-unsaturated derivative.
Next, compound 8 was converted into the corresponding
4,6-O-(2-naphthyl)methylene derivative 11 by oxidative ring
closure with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) 146
(Scheme 4). It was followed by the key step of the synthesis,
glycosylation of monosaccharide acceptor 12[26] with the new,
non-participating L-idosyl donor 11. We demonstrated earlier
that glycosylation reaction between the 2,3-di-O-benzyl conge-
ner of 11 and a GlcNAc acceptor of low reactivity proceeded 151
with full 1,2-trans-α-selectivity.[16] However, it was questionable
whether donor 11 was able to ensure complete stereoselecti-
vity when reacting with an acceptor of higher reactivity. To our
great delight, condensation of acceptor 12 and donor 11 upon
iodonium ion activation resulted in the desired α-linked GH 156
disaccharide with full stereoselectivity in high yield and in crys-
talline form. The exclusive α-stereoselectivity can be explained
by the steric hindrance of the C2-protecting group to prevent
nucleophilic attack from the -face and by the controlling ef-
fect[27,28] of the 4,6-O-cyclic protecting group which has been 161
demonstrated to ensure α-selectivity in D-glucosylation and D-
galactosylation reactions.
Scheme 4. Preparation of GH disaccharide 13 and its transformations to ac-
ceptors 14 and 16.
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Conversion of the fully protected disaccharide 13 to an ac-
ceptor by regioselective ring opening reaction was first at-
tempted with a BF3·Et2O/Et3SiH[29] reagent combination. Unfor-166
tunately, the main product of the reaction was diol 15 and the
expected 6′-ether 14 was only formed in a low 20 % yield.
Hence, we turned to the Me3N·BH3/AlCl3 reagent system which
is known to cleave the 4,6-O-acetals with a solvent dependent
regioselectivity.[26,30] In THF, the required 4′-OH/6′-O-ether 14171
was isolated as the only product in 80 % yield. Diol 15 was also
converted to a disaccharide acceptor building block by regio-
selective silylation of the primary hydroxyl group. Treatment of
15 with tert-butyldiphenylsilyl chloride (TBDPSCl) in dry pyrid-
ine provided acceptor 16 in excellent yield.176
Glycosylation of disaccharide 16 with thioglycoside donor
17[31] upon iodonium ion activation resulted in FGH trisacchar-
ide 18 with the desired α-interglycosidic linkage in 88 % yield
(Scheme 5).
Scheme 5. Synthesis of the FGH disaccharide acceptors 19a and 21a.
Conversion of 18 to acceptor 19a was achieved again by a181
regioselective ring-opening reaction using the Me3N·BH3/AlCl3
reagent system in THF to produce the desired product in 65 %
yield along with the regioisomeric by-product 19b isolated in
21 %. Following the above reaction path, the 6′-ONAP-contain-
ing 14 was converted to another trisaccharide acceptor, com-186
pound 21a, with similar efficacy.
The assembly of the non-oxidized precursor of the final prod-
uct idraparinux was initially carried out by glycosylation of tri-
saccharide acceptor 19a with the non-glucuronide type DE di-
saccharide donor 22[32] (Scheme 6). Surprisingly, condensation191
of disaccharide 22 and trisaccharide 19a upon NIS-AgOTf acti-
vation provided the DEH trisaccharide 24 as the major product
in 46 % yield, and the needed pentasaccharide 23 was formed
in a very low yield of 11 %.
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Scheme 6. Synthesis of the protected pentasaccharide 23 by applying the
silyl-containing acceptor 19a.
The formation of trisaccharide 24 can be explained either by 196
direct attack of the α-L-idosyl glycosidic oxygen onto the ano-
meric carbon of the dioxolenium ion formed from 22 or by
an intramolecular glycosyl transfer reaction via the orthoester
intermediate 23a (Scheme 7). The intermolecular glycosyl trans-
fer to 22a could only occur if 019a adopts a conformation in 201
which the free hydroxyl group is extremely shielded thereby the
attack of the interglycosidic oxygen, nucleophilicity of which is
enhanced by the surrounding electron-donating ether substitu-
ents, becomes dominant. Another, more probable mechanism
is the formation of orthoester 23a which then can undergo 206
either a conventional rearrangement to give the expected
Scheme 7. Plausible mechanism of the formation of DEH trisaccharide 24.
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pentasaccharide 23 or can be transformed to trisaccharide 24
by intramolecular transfer of unit H onto the glycosidic center
of unit E.
In the hope of a more efficient synthesis of the protected211
pentasaccharide skeleton, disaccharide 22 was treated with
the NAP-group-containing disaccharide acceptor 21a upon NIS-
TfOH activation. This case the [2+3] coupling reaction pro-
ceeded with high efficacy to provide the expected protected
pentasaccharide 25 with complete -stereoselectivity, in 70 %216
yield (Scheme 8). The significant difference in the DE+FGH cou-
pling outcome upon changing a remote protecting group in
the acceptor FGH (19a vs. 21a) can be explained by the differ-
ent steric and electronic properties of the TBDMS and the NAP
Scheme 8. The [2+3] coupling reaction with the NAP-containing trisaccharide
acceptor 21a.
Scheme 9. The transformation of the 6-O-NAP containing protected pentasac-
charide.
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protecting group. Another possible reason for the different effi- 221
cacy of the two glycosylations is that different promoter sys-
tems were applied in the two coupling reactions. We hypothe-
size that under the NIS-AgOTf promotion the orthoester forma-
tion may be more preferred compared to the NIS-TfOH promo-
tion. As the formation of the needed pentasaccharide pro- 226
ceeded with high efficacy with acceptor 21a, we did not study
further the intriguing behavior of acceptor 19a.
The synthesis was continued with the NAP-containing penta-
saccharide 25 of which we had a sufficient amount for the re-
maining transformations (Scheme 9). First, compound 25 was 231
subjected to Zemplén deacetylation to produce diol 26. Intro-
duction of the methyl ethers to the freed hydroxyls was accom-
plished by standard alkylation using methyl iodide and sodium
hydride to afford the desired compound 27 in 80 % yield. Next,
the primary hydroxyls that were to be oxidized in units E and 236
G were liberated in one step by oxidative cleavage of the NAP
groups with DDQ[33] to provide diol 28[14] in 70 % yield. The
final transformations of 28 into idraparinux, involving TEMPO-
BAIB-mediated oxidation, removal of benzyl ethers by catalytic
hydrogenation and O-sulfation using SO3·Et3N, were performed 241
according to our previous method.[14]
Conclusions
We have developed a new approach to the synthesis of idrapar-
inux in which the novel and efficient preparation of a 4,6-O-
acetal-containing L-idose donor and its utilization for the syn- 246
thesis of the GH disaccharide fragment were the key steps. The
synthesis of the new idosyl donor was achieved from a properly
protected α-thioglucoside in four steps including AgF-mediated
elimination, stereoselective hydroboration using BH3·THF,
chemoselective oxidation with H2O2 and DDQ-mediated oxid- 251
ative acetal ring-closure. By applying this donor, due to the con-
trolling effect of the 4,6-acetal group, the GH building block
was prepared with full 1,2-trans-α-stereoselectivity in the ab-
sence of a participating group at C2 position. Typically, L-idose
or L-iduronic acid donors with a C2 participating group have 256
been applied for the construction of the α-L-idosyl glycosidic
linkage.[10,34] The demonstrated α-stereodirecting effect of the
4,6-cyclic acetal in the presence of an ether protecting group
at C2 position pave the way to designing new, more diverse
protecting group strategies for the synthesis of heparin and 261
heparin sulfate oligosaccharides. Another advantage of this
new strategy to GH unit is that most synthetic intermediates
were obtained in crystalline form. The idopyranosyl-containing
GH unit was successfully incorporated to a late-stage oxidation
strategy whereby the non-oxidized pentasaccharide backbone 266
was created by an F+GH and DE+FGH coupling sequence, with
full stereoselectivity in each glycosylation step, followed by si-
multaneous formation of two carboxylic functions at the penta-
saccharide level.
Applying this new approach the target pentasaccharide 3 271
could be achieved in a 38-step synthesis starting from D-gluc-
ose and methyl α-D-glucopyranoside with 23 steps for the long-
est linear route. To the best of our knowledge, this is the short-
est route to idraparinux yet reported.
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Experimental Section276
General Information: Optical rotations were measured at room
temperature on a Perkin–Elmer 241 automatic polarimeter. TLC
analysis was performed on Kieselgel 60 F254 (Merck) silica-gel plates
with visualization by immersing in a sulfuric-acid solution (5 % in
EtOH) followed by heating. Column chromatography was per-281
formed on silica gel 60 (Merck 0.063–0.200 mm) and Sephadex LH-
20 (Sigma–Aldrich, bead size: 25–100 mm). Organic solutions were
dried with MgSO4 and concentrated under vacuum. 1H and 13C
NMR spectroscopy (1H: 400 and 500 MHz; 13C: 100.28 and
125.76 MHz) were performed on Bruker DRX-400 and Bruker Avance286
II 500 spectrometers at 25 °C. Chemical shifts are referenced to
SiMe4 or sodium 3-(trimethylsilyl)-1-propanesulfonate (DSS, δ =
0.00 ppm for 1H nuclei) and to solvent signals (CDCl3: δ =
77.00 ppm, CD3OD: δ = 49.15 ppm for 13C nuclei). MALDI-TOF MS
analyses of the compounds were carried out in the positive reflek-291
tron mode using a BIFLEX III mass spectrometer (Bruker, Germany)
equipped with delayed-ion extraction. 2,5-Dihydroxybenzoic acid
(DHB) was used as matrix and F3CCOONa as cationising agent in
DMF. HRMS measurements were carried out on a maXis II UHR ESI-
QTOF MS instrument (Bruker) in positive ionization mode. The fol-296
lowing parameters were applied for the electrospray ion source:
capillary voltage: 3.6 kV; end plate offset: 500 V; nebulizer pressure:
0.5 bar; dry gas temperature: 200 °C and dry gas flow rate: 4.0 L/
min. Constant background correction was applied for each spec-
trum, the background was recorded before each sample by inject-301
ing the blank sample matrix (solvent). Na-formate calibrant was in-
jected after each sample which enabled internal calibration during
data evaluation. Mass spectra were recorded by otofControl version
4.1 (build: 3.5, Bruker) and processed by Compass DataAnalysis ver-
sion 4.4 (build: 200.55.2969).306
Ethyl 2,3-Di-O-methyl-4,6-O-(2-naphthyl)methylene-1-thio-α-D-
glucopyranoside (5): Compound 4[20] (540 mg, 1.766 mmol) was
dissolved in dry DMF (8.0 mL) and NaH (60 %, 170 mg, 4.238 mmol,
1.2 equiv./OH) was slowly added to the solution at 0 °C. After stir-
ring for 30 min at 0 °C, MeI (275 μL, 4.415 mmol, and 1.25 equiv./311
OH) was added. When complete conversion of the starting material
into a main spot had been observed by TLC analysis (24 h at room
temperature), CH3OH (2.5 mL) was added. The reaction mixture was
stirred for 5 min and the solvents were evaporated. The residue was
dissolved in CH2Cl2 (100 mL), and washed with H2O (2 × 35 mL),316
the organic layer was dried, filtered and the solvents evaporated.
The crude product was purified by column chromatography (7:3 n-
hexane/acetone) to give 5 (634 mg, 92 %) as white crystals. [α]D25 =
+203.6 (c = 0.14, CHCl3); m.p.: 145–147 °C (EtOAc/n-hexane); Rf 0.43
(7:3 n-hexane/acetone). 1H NMR (CDCl3, 500 MHz): δ = 7.97–7.47321
(m, 7 H, arom), 5.70 (s, 1 H, Hac), 5.54 (d, J = 4.9 Hz, 1 H, H-1), 4.34–
4.28 (m, 2 H, H-5, H-6a), 3.83–3.79 (m, 1 H, H-6b), 3.64 (s, 3 H, OCH3),
3.61–3.56 (m, 3 H, H-2, H-3, H-4), 3.52 (s, 3 H, OCH3), 2.65–2.54 (m,
2 H, SCH2CH3), 1.31 (t, J = 7.4 Hz, 3 H, SCH2CH3) ppm. 13C NMR
(CDCl3, 125 MHz): δ = 134.8, 133.8, 133.0 (3C, 3 × Cq arom), 128.5–326
123.9 (7C, arom), 101.8 (1C, Cac), 83.8 (1C, C-1), 82.4, 81.4, 80.3 (3C,
C-2, C-3, C-4), 69.1 (1C, C-6), 62.9 (1C, C-5), 61.3, 58.6 (2C, 2 × OCH3),
24.0 (1C, SCH2CH3), 14.9 (SCH2CH3) ppm. MS (ESI-TOF): m/z calcd.
for C21H26NaO5S: 413.1393 [M + Na]+, found 413.1403.
Ethyl 2,3-Di-O-methyl-4-O-(2-naphthyl)methyl-1-thio-α-D-331
glucopyranoside (6): To a stirred solution of the 4,6-O-acetal deriv-
ative 5 (1.53 g, 3.918 mmol) in a mixture of dry CH2Cl2 (44 mL) and
dry Et2O (18 mL) were added successively LiAlH4 (669 mg,
17.631 mmol, 4.5 equiv.) and a solution of AlCl3 (784 mg,
5.877 mmol, 1.5 equiv.) in dry Et2O (11 mL) under argon at 0 °C.336
When the TLC (6:4 n-hexane/EtOAc) indicated complete disappear-
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ance of the starting material (1 h), the reaction mixture was cooled
in an ice-bath, and the excess of reagent was decomposed by care-
ful addition of EtOAc (79 mL) followed by H2O (19 mL), and the
stirring was continued for additional 5 min. The mixture obtained, 341
consisting of a grey, non-filterable suspension and a clear organic
phase, was poured into a separating funnel and diluted with EtOAc
(200 mL). The layers were separated and the organic phase was
washed with H2O (3 × 50 mL), dried with MgSO4 and concentrated.
The residue was purified by column chromatography (6:4 n-hexane/ 346
EtOAc) to give 6 (1.38 g, 90 %) as white crystals. [α]D25 = +230.0 (c =
0.10, CHCl3); m.p.: 103–105 °C (EtOAc/n-hexane); Rf 0.43 (7:3 n-hex-
ane/acetone). 1H NMR (CDCl3, 400 MHz): δ = 7.84–7.44 (m, 7 H,
arom), 5.48 (d, J = 5.1 Hz, 1 H, H-1), 5.03 (d, J = 11.4 Hz, 1 H, NAP-
CH2a), 4.83 (d, J = 11.4 Hz, 1 H, NAP-CH2b), 4.09 (dt, J = 3.3, J = 351
8.9 Hz, 1 H, H-5), 3.83–3.73 (m, 3 H), 3.66, 3.50 (2 × s, 6 H, 2 × OCH3),
3.57–3.47 (m, 2 H), 2.61–2.50 (m, 2 H, SCH2CH3), 1.74 (t, 1 H, H-6-
OH), 1.28 (t, J = 7.4 Hz, 3 H, SCH2CH3) ppm. 13C NMR (CDCl3,
100 MHz): δ = 135.8, 133.4, 133.1 (3C, 3 × Cq arom), 128.3–126.1
(7C, arom), 84.3 (1C, C-1), 82.8, 82.0, 77.5, 71.1 (4C, skeleton car- 356
bons), 75.0 (1C, NAP-CH2), 62.1 (1C, C-6), 61.3, 58.3 (2C, 2 × OCH3),
24.0 (1C, SCH2CH3), 14.8 (1C, SCH2CH3) ppm. MS (ESI-TOF): m/z
calcd. for C21H28NaO5S: 415.1550 [M + Na]+, found 415.1574.
C21H28KO5S: 431.1289 [M + Na]+, found 431.1286.
Ethyl 6-Deoxy-6-iodo-2,3-di-O-methyl-4-O-(2-naphthyl)methyl- 361
1-thio-α-D-glucopyranoside (7): To the solution of thioglucoside
6 (419 mg, 1.068 mmol) in dry toluene (6.3 mL), triphenylphosphine
(420 mmol, 1.602 mmol, 1.5 equiv.), imidazole (218 mg, 3.204 mmol,
3.0 equiv.) and iodine (387 mg, 1.495 mmol, 1.4 equiv.) were added.
The reaction mixture was stirred at 75 °C for 30 min then cooled to 366
room temperature. To the stirred mixture NaHCO3 (210 mg) in water
(2.6 mL) was added at room temperature. After 5 min 10 % aqueous
solution of Na2S2O3 (5.0 mL) was added and the mixture was di-
luted with EtOAc (125 mL) and washed with H2O (2 × 35 mL). The
organic layer was separated, dried with MgSO4 and concentrated 371
under reduced pressure. The crude product was purified by column
chromatography (8:2 n-hexane/EtOAc) to give 7 (450 mg, 84 %) as
white crystals. [α]D25 = +146.0 (c = 0.40, CHCl3); m.p.: 82–84 °C
(EtOAc/n-hexane); Rf 0.41 (8:2 n-hexane/EtOAc). 1H NMR (CDCl3,
400 MHz): δ = 7.85–7.45 (m, 7 H, arom), 5.50 (d, J = 4.7 Hz, 1 H, H- 376
1), 5.08 (d, J = 11.2 Hz, 1 H, NAP-CH2a), 4.88 (d, J = 11.2 Hz, 1 H,
NAP-CH2b), 3.87–3.83 (m, 1 H, H-5), 3.64, 3.50 (2 × s, 6 H, 2 × OCH3),
3.55–3.53 (m, 2 H, H-2, H-3), 3.49–3.47 (m, 1 H, H-6a), 3.40 (dd, J =
5.5, J = 10.7 Hz, 1 H, H-6b), 3.34 (t, J = 8.8 Hz, 1 H, H-4), 2.69–2.58
(m, 2 H, SCH2CH3), 1.29 (t, J = 7.4 Hz, 3 H, SCH2CH3) ppm. 13C NMR 381
(CDCl3, 100 MHz): δ = 135.7, 133.4, 133.1 (3C, 3 × Cq arom), 128.4–
126.0 (7C, arom), 84.0 (1C, C-2), 82.6 (1C, C-1), 81.9 (1C, C-3), 81.5
(1C, C-4), 75.3 (1C, NAP-CH2), 69.4 (1C, C-5), 61.2, 58.2 (2C, 2 × OCH3),
24.0 (1C, SCH2CH3), 14.8 (1C, SCH2CH3), 8.2 (1C, C-6) ppm. MS (ESI-
TOF): m/z calcd. for C21H27INaO4S: 525.0567 [M + Na]+, found 386
525.0567.
Ethyl 2,3-Di-O-methyl-4-O-(2-naphthyl)methyl-1-thio--L-ido-
pyranoside (8), Ethyl 2,3-Di-O-methyl-4-O-(2-naphthyl)methyl-
1-thio--L-idopyranoside Sulfoxide (9) and Ethyl 6-Deoxy-6-
fluoro-2,3-di-O-methyl-4-O-(2-naphthyl)methyl-1-thio-α-D-gluco-391
pyranoside (10): Method I.: A vigorously stirred solution of iodide
7 (1.38 g, 2.746 mmol) in dry DMF (23 mL) was cooled to 0 °C, NaH
(132 mg, 5.494 mmol, 2.0 equiv.) was added and the reaction mix-
ture was stirred at room temperature for 24 h. After the complete
disappearance of the starting material, MeOH (2.0 mL) was added 396
and the mixture was concentrated. The residue was dissolved in
CH2Cl2 (250 mL) and washed with H2O (2 × 50 mL). The organic
layer was separated, dried with MgSO4 and concentrated under re-
duced pressure. To a stirred solution of the crude product (954 mg,
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2.548 mmol) in anhydrous THF (6.5 mL) a solution of BH3·THF com-401
plex in THF (1 M, 25.5 mL, 25.487 mmol, 10.0 equiv.) was added at
0 °C. The reaction mixture was kept at this temperature for 1.5 h.
Then H2O2 (30 %, 6.5 mL) and an aqueous solution of NaOH (2M,
13.5 mL) were added at 0 °C and the reaction mixture was stirred
at room temperature for 50 min. Subsequently, the reaction mixture406
was diluted with EtOAc (150 mL) and washed with saturated aque-
ous solution of NH4Cl (2 × 25 mL), H2O (25 mL) and brine (25 mL).
The organic layer was separated, dried with MgSO4 and concen-
trated under reduced pressure. The residue was purified by column
chromatography (7:3 n-hexane/acetone) to give 8 (411 mg, 41 %411
for three steps) as a colorless syrup and 6 and 9 (100 mg, ≈ 10 %
inseparable mixture, ratio of 6:9 ≈ 3:1) as a colorless syrup.
Method II: A vigorously stirred solution of iodide 7 (440 mg,
0.876 mmol) in dry pyridine (8.8 mL) AgF (556 mg, 4.379 mmol,
5.0 equiv.) was added and the reaction mixture was stirred in the416
dark at room temperature for 24 h. After the complete disappear-
ance of the starting material the mixture was diluted with EtOAc
(15 mL), filtered through a pad of Celite® and concentrated under
reduced pressure. To a stirred solution of the crude product
(300 mg, 0.801 mmol) in anhydrous THF (2.0 mL) a solution of421
BH3·THF complex in THF (1M, 8.0 mL, 8.011 mmol, 10.0 equiv.) was
added at 0 °C. The reaction mixture was kept at this temperature
for 1.5 h. Then H2O2 (30 %, 2.0 mL) and an aqueous solution of
NaOH (2M, 4.25 mL) were added at 0 °C and the reaction mixture
was stirred at room temperature for 50 min. Subsequently, the reac-426
tion mixture was diluted with EtOAc (100 mL) and washed with
saturated aqueous solution of NH4Cl (2 × 15 mL), H2O (15 mL) and
brine (15 mL). The organic layer was separated, dried with MgSO4
and concentrated under reduced pressure. The residue was purified
by column chromatography (6:4 n-hexane/acetone) to give 8431
(204 mg, 66 % for three steps) as a colorless syrup and 6 and 9
(34 mg, ≈ 11 % inseparable mixture, ratio of 6:9 ≈ 2:1) as a colorless
syrup and 10 (34 mg, 11 %).
Data of the Mixture of 6 and 9: Characteristic NMR signals: 1H
NMR (CDCl3, 400 MHz): δ = 5.45 (d, J = 5.1 Hz, 1 H, H-1 D-gluco),436
5.12 (d, J = 2.2 Hz, 0.5 H, H-1 L-ido-sulfoxide). MS (MALDI-TOF): m/z
calcd. for C21H28NaO5S (6): 415.155 [M + Na]+, found 415.292; m/z
calcd. for C21H28NaO6S (9): 431.151 [M + Na]+, found 431.246.
Data of 8: [α]D25 = +52.0 (c = 0.55, CHCl3); Rf 0.25 (7:3 n-hexane/
acetone). 1H NMR (CDCl3, 400 MHz): δ = 7.85–7.47 (m, 7 H, arom),441
4.81 (d, J = 12.4 Hz, 1 H, NAP-CH2a), 4.80 (d, J = 1.6 Hz, 1 H, H-1),
4.70 (d, J = 12.5 Hz, 1 H, NAP-CH2b), 4.02 (dd, J = 7.9, J = 11.5 Hz, 1
H, H-6a), 3.78 (ddd, J = 1.9, J = 4.3, J = 6.6 Hz, 1 H, H-5), 3.60–3.57
(m, 2 H, H-3, H-6b), 3.51 (s, 3 H, OCH3), 3.41 (s, 1 H, H-4), 3.30 (s, 4
H, H-2, OCH3), 2.71 (qd, J = 2.8, J = 7.4 Hz, 2 H, SCH2CH3), 1.99 (s, 1446
H, H-6-OH), 1.28 (t, J = 7.4 Hz, 3 H, SCH2CH3) ppm. 13C NMR (CDCl3,
100 MHz): δ = 135.4, 133.2, 133.1 (3C, 3 × Cq arom), 128.5–126.2
(7C, arom), 83.4 (1C, C-1), 78.5 (1C, C-2), 77.3 (1C, C-5), 73.3 (1C, C-
3), 72.4 (1C, NAP-CH2), 71.4 (1C, C-4), 62.8 (1C, C-6), 59.2, 58.1 (2C,
2 × OCH3), 25.8 (1C, SCH2CH3), 15.5 (1C, SCH2CH3) ppm. MS (ESI-451
TOF): m/z calcd. for C21H28NaO5S: 415.1550 [M + Na]+, found
415.1552.
Data of 10: [α]D25 = +184.0 (c = 0.20, CHCl3); Rf 0.64 (6:4 n-hexane/
acetone). 1H NMR (CDCl3, 400 MHz): δ = 7.85–7.44 (m, 7 H, arom),
5.51 (d, J = 4.0 Hz, 1 H, H-1), 5.05 (d, J = 11.3 Hz, 1 H, NAP-CH2a),456
4.80 (d, J = 11.3 Hz, 1 H, NAP-CH2b), 4.67 (ddd, J = 3.3, J = 10.3 Hz,
J = 47.2 Hz, 1 H, H-6a), 4.55 (ddd, J = 1.5, J = 10.3, J = 47.3 Hz, 1 H,
H-6b), 4.24–4.14 (m, H-5), 3.66 (s, 3 H, OCH3), 3.55–3.52 (m, 3 H, H-
2, H-3, H-4), 3.51 (s, 3 H, OCH3), 2.57 (tdd, J = 5.4, J = 7.4, J = 12.8 Hz,
2 H, SCH2CH3), 1.29 (t, J = 7.4 Hz, 3 H, SCH2CH3) ppm. 13C NMR461
(CDCl3, 100 MHz): δ = 135.7, 133.4, 133.2 (3C, 3 × Cq arom), 128.4–
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126.0 (7C, arom), 84.3 (1C, C-1), 82.3 (d, J = 172 Hz, 1C, C-6), 83.0,
81.8 (2C, C-2, C-3), 76.7 (d, J = 5.9 Hz, 1C, C-4), 75.3 (1C, NAP-CH2),
70.2 (d, J = 18.1 Hz, 1C, C-5), 61.3, 58.3 (2C, 2 × OCH3), 24.1 (1C,
SCH2CH3), 14.8 (1C, SCH2CH3) ppm. MS (ESI-TOF): m/z calcd. for 466
C21H27FNaO4S: 417.1506 [M + Na]+, found 417.1506.
Ethyl 2,3-Di-O-methyl-4,6-O-(2-naphthyl)methylene-1-thio--L-
idopyranoside (11): To a vigorously stirred solution of 8 (160 mg,
0.407 mmol) in dry CH2Cl2 (11 mL) DDQ (139 mg, 0.611 mmol,
1.5 equiv.) and 4 Å MS (115 mg) were added. After 50 min the 471
mixture was diluted with CH2Cl2 (100 mL), filtered, extracted with a
saturated aqueous solution of NaHCO3 (2 × 25 mL) and H2O (2 ×
25 mL), dried and concentrated. The crude product was purified by
silica gel chromatography (7:3 n-hexane/acetone) to give 11
(106 mg, 67 %) as a colorless syrup. [α]D25 = +55.7 (c = 0.21, CHCl3); 476
Rf 0.35 (7:3 n-hexane/acetone). 1H NMR (CDCl3, 400 MHz): δ = 7.96–
7.44 (m, 7 H, arom), 5.62 (s, 1 H, Hac), 4.87 (d, J = 1.3 Hz, 1 H, H-1),
4.36 (d, J = 12.5 Hz, 1 H, NAP-CH2a), 4.07 (dd, J = 2.0, J = 12.5 Hz, 1
H, NAP-CH2b), 3.97 (s, 1 H, H-4), 3.70 (t, J = 2.2 Hz, 1 H, H-3), 3.58
(d, J = 1.1 Hz, 1 H, H-5), 3.49, 3.47 (2 × s, 6 H, 2 × OCH3), 3.36 (s, 1 481
H, H-2), 2.76 (q, J = 7.4 Hz, 2 H, SCH2CH3), 1.31 (t, J = 7.4 Hz, 3 H,
SCH2CH3) ppm. 13C NMR (CDCl3, 100 MHz): δ = 135.8, 133.8, 133.0
(3C, 3 × Cq arom), 128.4–124.6 (7C, arom), 101.6 (1C, Cac), 82.3 (1C,
C-1), 77.2 (1C, C-2), 75.4 (1C, C-3), 71.7 (1C, C-4), 70.1 (1C, C-6), 68.6
(1C, C-5), 58.4, 58.2 (2C, 2 × OCH3), 25.6 (1C, SCH2CH3), 15.1 (1C, 486
SCH2CH3) ppm. MS (ESI-TOF): m/z calcd. for C21H26NaO5S: 413.1393
[M + Na]+, found 413.1393.
Methyl [2,3-Di-O-methyl-4,6-O-(2-naphthyl)methylene-α-L-ido-
pyranosyl]-(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (13):
To a solution of compound 11 (200 mg, 0.512 mmol) and com- 491
pound 12[26] (357 mg, 0.768 mmol, 1.5 equiv.) in dry CH2Cl2 (6.0 mL)
4 Å molecular sieves (0.25 g) were added. After stirring at room
temperature for 30 min, the mixture was cooled to –40 °C and
solutions of NIS (173 mg, 0.768 mmol, 1.5 equiv.) in dry THF (240 μL)
and AgOTf (32 mg, 0.123 mmol, 0.24 equiv.) in dry toluene (240 μL) 496
were added. After stirring at –40 °C to –20 °C for 4 h, TLC analysis
(6:4 n-hexane/EtOAc) showed complete consumption of the donor.
The reaction mixture was neutralized with Et3N (50 μL), diluted with
CH2Cl2 (150 mL), and filtered. The filtrate was washed with an aque-
ous solution of Na2S2O3 (10 %, 25 mL), a saturated aqueous solution 501
of NaHCO3 (2 × 25 mL), and water (2 × 25 mL), dried, and concen-
trated. The crude product was purified by column chromatography
on silica gel (6:4 n-hexane/EtOAc) to give compound 13 (294 mg,
72 %) as white crystals. [α]D25 = +1.1 (c = 0.09, CHCl3); Rf 0.36 (6:4 n-
hexane/EtOAc); m.p.: 162–164 °C (EtOAc/n-hexane). 1H NMR (CDCl3, 506
400 MHz): δ = 7.91–7.22 (m, 22 H, arom), 5.43 (s, 1 H, Hac), 5.05 (d,
J = 11.2 Hz, 1 H, Bn-CH2a), 4.85 (d, J = 4.9 Hz, 1 H, H-1′), 4.78–4.56
(m, 6 H, Bn-CH2b, 2 × Bn-CH2, H-1), 3.98–3.77 (m, 5 H, H-3, H-4, H-
4′, H-5′, H-6′a), 3.70–3.69 (m, 2 H, H-6a,b), 3.59 (dd, J = 3.6, J =
9.5 Hz, 1 H, H-2), 3.54 (s, 1 H, H-5), 3.51 (s, 3 H, OCH3), 3.46–3.43 (m, 511
1 H, H-3′), 3.44, 3.38 (2 × s, 6 H, 2 × OCH3), 3.20 (dd, J = 4.9, J =
9.1 Hz, 1 H, H-2′), 3.16 (dd, J = 2.2, J = 13.2 Hz, 1 H, H-6′b) ppm.
13C NMR (CDCl3, 100 MHz): δ = 139.2, 138.1, 137.8, 135.5, 133.6,
132.9 (6C, 6 × Cq arom), 128.5–124.0 (22C, arom), 100.4, (1C, C-1′),
100.0 (1C, Cac), 98.1 (1C, C-1), 82.3 (1C, C-3), 80.6 (1C, C-2), 80.3, 80.2 516
(2C, C-2′, C-3′), 78.2 (1C, C-4′), 75.7, 73.5, 73.4 (3C, 3 × Bn-CH2), 73.0
(1C, C-4), 70.6 (1C, C-5), 68.7 (1C, C-6′), 68.5 (1C, C-6), 62.0 (1C, C-5′),
59.8, 58.6 (2C, 2 × OCH3), 55.2 (1C, C-1-OCH3) ppm. MS (ESI-TOF):
m/z calcd. for C47H52NaO11: 815.3402 [M + Na]+, found 815.3399.
Methyl [2,3-Di-O-methyl-6-O-(2-naphthyl)methyl-α-L-idopyranosyl]- 521
(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (14) and Methyl (2,3-
Di-O-methyl-α-L-idopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-gluco-
pyranoside (15)
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Method I: To a solution of compound 13 (250 mg, 0.315 mmol) in
anhydrous CH2Cl2 (3.2 mL) at 0 °C Et3SiH (604 μL, 3.784 mmol,526
12.0 equiv.) and BF3·Et2O (80 μL, 0.631 mmol, 2.0 equiv.) were
added. The reaction mixture was stirred for 2 h at 0 °C. Than the
mixture was diluted with CH2Cl2 (100 mL), washed with saturated
aqueous solution of NaHCO3 (2 × 20 mL), dried with MgSO4 and
concentrated. The crude product was purified by column chroma-531
tography on silica gel (1:1 n-hexane/EtOAc) to give compound 14
(52 mg, 20 %) as a colorless syrup and compound 15 (105 mg,
42 %) as a colorless syrup.
Method II: To a solution of compound 13 (126 mg, 0.159 mmol) in
anhydrous THF (500 μL) 4 Å MS (121 mg) and Me3N·BH3 (70 mg,536
0.953 mmol, 6.0 equiv.) were added and stirred for 30 min at room
temperature. After 30 min AlCl3 (127 mg, 0.953 mmol, 6.0 equiv.)
was added and the reaction mixture was stirred at room tempera-
ture for 30 min. The mixture was diluted with CH2Cl2 (100 mL),
washed with water (2 × 20 mL), dried with MgSO4 and concen-541
trated. The crude product was purified by column chromatography
on silica gel (1:1 n-hexane/EtOAc) to give compound 14 (101 mg,
80 %) as a colorless syrup.
Data of 14: [α]D25 = +3.3 (c = 0.12, CHCl3); Rf 0.40 (1:1 n-hexane/
EtOAc). 1H NMR (CDCl3, 400 MHz): δ = 7.80–7.20 (m, 22 H, arom),546
5.08 (s, 1 H, H-1′), 4.95–4.43 (m, 9 H, NAP-CH2, 3 × Bn-CH2, H-1), 4.39
(td, J = 1.3, J = 5.7 Hz, 1 H, H-5′), 3.94–3.86 (m, 2 H), 3.79–3.57 (m,
5 H), 3.52–3.46 (m, 3 H), 3.40, 3.34, 3.27 (3 × s, 9 H, 3 × OCH3), 3.20
(s, 1 H), 3.14 (d, J = 9.3 Hz, 1 H, C-4-OH) ppm. 13C NMR (CDCl3,
100 MHz): δ = 139.2, 138.2, 138.0, 135.9, 133.3, 132.9 (6C, 6 × Cq551
arom), 128.4–125.7 (22C, arom), 98.1 (2C, C-1, C-1′), 80.4, 80.3, 77.5,
77.4, 74.6, 70.1, 66.9, 66.8 (8C, skeleton carbons), 75.4, 73.5, 73.3
(4C, NAP-CH2, 3 × Bn-CH2), 69.8, 68.9 (2C, C-6, C-6′), 58.5, 58.3 (2C,
2 × OCH3), 55.2 (1C, C-1-OCH3) ppm. MS (MALDI-TOF): m/z calcd. for
C47H54NaO11: 817.356 [M + Na]+, found 817.381.556
Data of 15: [α]D25 = –5.5 (c = 0.20, CHCl3); Rf 0.13 (1:1 n-hexane/
EtOAc). 1H NMR (CDCl3, 400 MHz): δ = 7.27–7.18 (m, 15 H, arom),
4.96 (d, J = 10.5 Hz, 1 H, Bn-CH2a), 4.89 (s, 1 H, H-1′), 4.72–4.45 (m,
6 H, Bn-CH2b, 2 × Bn-CH2, H-1), 4.08–4.06 (m, 1 H, H-5′), 3.84–3.78
(m, 2 H, H-3, H-3′), 3.72–3.70 (m, 1 H, H-4), 3.56 (s, 2 H, H-6a,b), 3.51561
(dd, J = 3.3, J = 8.8 Hz, 1 H, H-2), 3.45–3.40 (m, 1 H, H-5), 3.37 (s, 3
H, OCH3), 3.35–3.31 (m, 1 H, H-4′), 3.29, 3.17 (2 × s, 6 H, 2 × OCH3),
3.28–3.12 (m, 2 H, H-6′a,b), 3.07–3.05 (m, 1 H, H-2′), 1.83 (s, 1 H, C-
6′-OH), 1.24 (s, 1 H, C-4′-OH) ppm. 13C NMR (CDCl3, 100 MHz): δ =
138.5, 138.0, 137.7 (3C, 3 × Cq arom), 128.5–127.7 (15C, arom), 98.0,566
(1C, C-1), 97.0 (1C, C-1), 80.3 (1C, C-2), 80.1 (1C, C-3), 76.9, 76.8 (2C,
C-2′, C-4′), 75.8, 73.6 (2C, 2 × Bn-CH2), 73.5 (1C, C-3′), 73.4 (1C, Bn-
CH2), 70.2 (1C, C-4), 68.9 (1C, C-6), 67.1, 67.0 (2C, C-5, C-5′), 63.0 (1C,
C-6′), 58.4, 58.2 (2C, 2 × OCH3), 55.2 (1C, C-1-OCH3) ppm. MS
(MALDI-TOF): m/z calcd. for C36H46NaO11: 667.293 [M + Na]+, found571
667.344.
Methyl (6-O-tert-Butyldiphenylsilyl-2,3-di-O-methyl-α-L-idopyr-
anosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (16): To a
solution of 15 (103 mg, 0.157 mmol) in dry pyridine (540 μL), tert-
butyldiphenylsilyl chloride (81 μL, 0.314 mmol, 2 equiv.) was added.576
The mixture was stirred for 24 h at room temperature. After the
complete disappearance of the starting material, the mixture was
concentrated. The residue was dissolved in EtOAc (75 mL), washed
with 1 M aqueous solution of HCl (2 × 10 mL), water (10 mL), satu-
rated aqueous solution of NaHCO3 (2 × 10 mL), and water (2 ×581
10 mL), dried, and concentrated. The crude product was purified by
column chromatography on silica gel (7:3 n-hexane/acetone) to
give compound 16 (114 mg, 81 %) as a colorless syrup. [α]D25 = +5.4
(c = 0.13, CHCl3); Rf 0.41 (7:3 n-hexane/acetone). 1H NMR (CDCl3,
400 MHz): δ = 7.69–7.15 (m, 25 H, arom), 5.08 (s, 1 H, H-1′), 4.88–586
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4.49 (m, 7 H, 3 × Bn-CH2, H-1), 4.26 (t, J = 5.1 Hz, 1 H, H-5′), 3.93–
3.84 (m, 2 H), 3.83–3.75 (m, 4 H), 3.69–3.61 (m, 2 H), 3.51–3.47 (m,
2 H), 3.41, 3.36, 3.24 (3 × s, 9 H, 3 × OCH3), 3.18 (s, 1 H), 1.26 (s, 1
H, C-4′-OH), 1.02 (s, 9 H, 3 × tBu-CH3) ppm. 13C NMR (CDCl3,
100 MHz): δ = 139.0, 138.3, 138.1, 133.4, 133.3 (5C, 5 × Cq arom), 591
129.6–127.3 (25C, arom), 98.4, 98.3 (2C, C-1, C-1′), 80.8, 80.2, 77.8,
77.6, 74.4, 70.0, 68.1, 66.7 (8C, skeleton carbons), 75.6, 73.6 (2C, 2 ×
Bn-CH2), 69.0 (1C, C-6), 63.5 (1C, C-6′), 58.4, 58.3 (2C, 2 × OCH3), 55.2
(1C, C-1-OCH3), 26.9 (3C, 3 × tBu-CH3), 19.2 (1C, Cq tBu) ppm. MS
(MALDI-TOF): m/z calcd. for C52H64NaO11Si: 915.411 [M + Na]+, 596
found 915.550.
Methyl (2,3-Di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranos-
yl)-(1→4)-(6-O-tert-butyldiphenylsilyl-2,3-di-O-methyl-α-L-ido-
pyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (18):
To a solution of compound 16 (54 mg, 0.060 mmol) and compound 601
17[31] (52 mg, 0.096 mmol, 1.6 equiv.) in dry CH2Cl2 (708 μL) 4 Å
molecular sieves (50 mg) were added. After stirring at room temper-
ature for 30 min, the mixture was cooled to –40 °C and solutions
of NIS (33 mg, 0.145 mmol, 1.5 equiv.) in dry THF (45 μL) and AgOTf
(6.0 mg, 0.023 mmol, 0.24 equiv.) in dry toluene (45 μL) were added. 606
After stirring at –40 °C to –20 °C for 4 h, TLC analysis (7:3 n-hexane/
EtOAc) showed complete consumption of the donor. The reaction
mixture was neutralized with Et3N (25 μL), diluted with CH2Cl2
(75 mL), and filtered. The filtrate was washed with an aqueous solu-
tion of Na2S2O3 (10 %, 10 mL), a saturated aqueous solution of NaH- 611
CO3 (2 × 10 mL), and water (2 × 10 mL), dried, and concentrated.
The crude product was purified by column chromatography on sil-
ica gel (7:3 n-hexane/EtOAc) to give compound 18 (70 mg, 88 %)
as a colorless syrup. [α]D25 = –1.8 (c = 0.11, CHCl3); Rf 0.30 (7:3 n-
hexane/EtOAc). 1H NMR (CDCl3, 500 MHz): δ = 7.74–7.19 (m, 40 H, 616
arom), 5.50 (s, 1 H, Hac), 5.28 (d, J = 3.9 Hz, 1 H, H-1′′), 5.01 (d, J =
7.2 Hz, 1 H, H-1′), 4.99–4.62 (m, 8 H, 4 × Bn-CH2), 4.62 (d, J = 3.6 Hz,
1 H, H-1), 4.49 (q, J = 12.2 Hz, 2 H, Bn-CH2), 4.01 (dd, J = 4.5, J =
10.1 Hz, 1 H, H-6′′a), 3.93–3.84 (m, 7 H, H-3, H-3′, H-3′′, H-4′, H-5, H-
6a, H-6′a), 3.77–3.75 (m, 2 H, H-5′, H-6′b), 3.65–3.56 (m, 5 H, H-2′′, 621
H-4, H-4′′, H-6b, H-6′′b), 3.55–3.52 (m, 1 H, H-5′′), 3.51 (s, 3 H, C-3′-
OCH3), 3.49–3.48 (m, 1 H, H-2), 3.46 (s, 3 H, C-2′-OCH3), 3.42 (s, 3 H,
C-1-OCH3), 3.00 (t, J = 7.7 Hz, 1 H, H-2′), 1.03 (s, 9 H, 3 × tBu-CH3)
ppm. 13C NMR (CDCl3, 125 MHz): δ = 139.5, 139.0, 138.6, 138.5,
138.3, 137.5, 132.9, 132.7 (8C, 8 × Cq arom), 129.9–126.2 (40C, arom), 626
101.2 (1C, Cac), 101.0 (1C, C-1′), 99.4 (1C, C-1′′), 98.1 (1C, C-1), 85.5
(1C, C-2′), 82.5 (1C, C-3′), 82.4 (1C, C-4′′), 80.6 (1C, C-3), 79.2 (1C, C-
2), 79.1 (1C, C-2′′), 78.9 (1C, C-4), 78.7 (1C, C-3′′), 75.9 (1C, C-4′), 75.6,
75.2 (2C, 2 × Bn-CH2), 73.8 (1C, C-5′), 73.7, 73.4 (3C, 3 × Bn-CH2),
70.8 (1C, C-5), 69.4 (1C, C-6), 68.8 (1C, C-6′′), 63.2 (1C, C-5′′), 62.8 631
(1C, C-6′), 60.6, 60.5 (2C, 2 × OCH3), 55.3 (1C, C-1-OCH3), 27.1 (3C,
3 × tBu-CH3), 19.1 (1C, Cq tBu) ppm. MS (MALDI-TOF): m/z calcd. for
C79H90NaO16Si:1345.589 [M + Na]+, found 1345.662.
Methyl (2,3,6-Tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-(6-O-tert-
butyldiphenylsilyl-2,3-di-O-methyl-α-L-idopyranosyl)-(1→4)- 636
2,3,6-tri-O-benzyl-α-D-glucopyranoside (19a) and Methyl (2,3,4-
Tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-(6-O-tert-butyldiphen-
ylsilyl-2,3-di-O-methyl-α-L-idopyranosyl)-(1→4)-2,3,6-tri-O-
benzyl-α-D-glucopyranoside (19b): To a solution of 18 (63 mg,
0.048 mmol) in dry THF (144 μL) 4 Å MS (36 mg) and Me3N·BH3 641
(21 mg, 0.286 mmol, 6 equiv.) were added and the reaction mixture
was stirred for 30 min at room temperature. After 30 min AlCl3
(38 mg, 0.286 mmol, 6 equiv.) was added and the mixture was
stirred at room temperature for 2 h. After 2.5 h the reaction mixture
was diluted with CH2Cl2 (5.0 mL), and washed with H2O (2 × 5 mL). 646
The organic layer was dried with MgSO4 and concentrated. The
crude product was purified by silica gel chromatography (7:3 n-
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hexane/acetone) to give 19a (40 mg, 65 %) as a colorless syrup and
19b (13 mg, 21 %) as a colorless syrup.
Data of 19a: [α]D25 = +13.0 (c = 0.13, CHCl3); Rf 0.36 (7:3 n-hexane/651
acetone). 1H NMR (CDCl3, 500 MHz): δ = 7.72–7.12 (m, 40 H, arom),
5.27 (d, J = 3.5 Hz, 1 H, H-1′′), 4.99 (d, J = 7.2 Hz, 1 H, H-1′), 4.97–
4.62 (m, 8 H, 4 × Bn-CH2), 4.60 (d, J = 3.6 Hz, 1 H, H-1), 4.52–4.40
(m, 4 H, 2 × Bn-CH2), 3.93 (dd, J = 4.7, J = 11.3 Hz, 1 H, H-6′a), 3.89–
3.83 (m, 6 H, H-3, H-3′, H-4, H-4′, H-5′, H-6a), 3.81–3.79 (m, 1 H, H-656
6′b), 3.67–3.56 (m, 4 H, H-3′′, H-4′′, H-5, H-6b), 3.54–3.49 (m, 2 H, H-
2′′, H-6′′a), 3.50 (s, 3 H, C-3′-OCH3), 3.47–3.46 (m, 1 H, H-2), 3.45 (s,
3 H, C-2′-OCH3), 3.41 (s, 3 H, C-1-OCH3), 3.42–3.35 (m, 2 H, H-5′′, H-
6′′b), 3.01 (t, J = 7.2 Hz, 1 H, H-2′), 2.24 (d, J = 2.5 Hz, 1 H, C-4′′-
OH), 1.04 (s, 9 H, 3 × tBu-CH3) ppm. 13C NMR (CDCl3, 125 MHz): δ =661
139.6, 139.0, 138.6, 138.5, 138.3, 138.0, 133.2, 132.9 (8C, 8 × Cq
arom), 129.9–127.2 (40C, arom), 100.8 (1C, C-1′), 98.6 (1C, C-1′′), 98.2
(1C, C-1), 85.1 (1C, C-2′), 82.1 (1C, C-3′), 81.4 (1C, C-3′′), 80.6
(1C, C-3), 79.2 (1C, C-2), 79.1 (1C, C-2′′), 78.8 (1C, C-4′′), 76.0 (1C,
C-4′), 75.6, 75.3, 73.8, 73.7 (4C, 4 × Bn-CH2), 73.6 (1C, C-4), 73.4, 72.5666
(2C, 2 × Bn-CH2), 70.9, 70.8, 70.7 (3C, C-5, C-5′, C-5′′), 69.3 (1C, C-6),
69.1 (1C, C-6′′), 62.8 (1C, C-6′), 60.5, 60.4 (2C, 2 × OCH3), 55.3 (1C,
C-1-OCH3), 27.1 (3C, 3 × tBu-CH3), 19.3 (1C, Cq tBu) ppm. MS (ESI-
TOF): m/z calcd. for C79H92NaO16Si: 1347.6047 [M + Na]+, found
1347.6037.671
Data of 19b: [α]D25 = +17.2 (c = 0.97, CHCl3); Rf 0.31 (7:3 n-hexane/
acetone). 1H NMR (CDCl3, 500 MHz): δ = 7.70–7.18 (m, 40 H, arom),
5.24 (d, J = 3.6 Hz, 1 H, H-1′′), 4.99 (d, J = 10.6 Hz, 1 H, Bn-CH2a),
4.96 (d, J = 7.0 Hz, 1 H, H-1′), 4.91–4.61 (m, 9 H, Bn-CH2b, 4 × Bn-
CH2), 4.60 (d, J = 3.0 Hz, 1 H, H-1), 4.47 (q, J = 12.2 Hz, 2 H, Bn-CH2),676
3.91 (dd, J = 4.9, J = 11.3 Hz, 1 H, H-6′a), 3.88–3.76 (m, 8 H, H-3, H-
3′, H-3′′, H-4′, H-5, H-5′, H-6a, H-6′b), 3.65 (t, J = 9.4 Hz, 1 H, H-4),
3.58 (dd, J = 7.0, J = 10.8 Hz, 1 H, H-6b), 3.53–3.46 (m, 5 H, H-2, H-
2′′, H-4′′, H-6′′a,b), 3.50 (s, 3 H, C-3′-OCH3), 3.46 (s, 3 H, C-2′-OCH3),
3.41 (s, 3 H, C-1-OCH3), 3.38–3.36 (m, 1 H, H-5′′), 3.00 (t, J = 7.2 Hz,681
1 H, H-2′), 1.48–1-45 (m, 1 H, C-6′′-OH), 1.04 (s, 9 H, 3 × tBu-CH3)
ppm. 13C NMR (CDCl3, 125 MHz): δ = 139.6, 138.5, 138.4, 133.2,
132.8, 131.2 (8C, 8 × Cq arom), 128.5–127.2 (40C, arom), 100.7 (1C,
C-1′), 98.6 (1C, C-1′′), 98.2 (1C, C-1), 85.2 (1C, C-2′), 82.3 (1C, C-3′),
81.8 (1C, C-3′′), 80.6 (1C, C-3), 79.7 (1C, C-2′′), 79.2 (1C, C-2), 78.8686
(1C, C-4), 77.5 (1C, C-4′′), 76.2 (1C, C-4′), 75.6, 75.2 (4C, 4 × Bn-CH2),
74.2 (1C, C-5′), 73.4, 72.8 (2C, 2 × Bn-CH2), 71.8 (1C, C-5′′), 70.8 (1C,
C-5), 69.3 (1C, C-6), 62.6 (1C, C-6′), 61.8 (1C, C-6′′), 60.5, 60.4 (2C, 2 ×
OCH3), 55.3 (1C, C-1-OCH3), 27.1 (3C, 3 × tBu-CH3), 19.2 (1C, Cq tBu)
ppm. MS (MALDI-TOF): m/z calcd. for C79H92NaO16Si: 1347.605 [M +691
Na]+, found 1347.877.
Methyl (2,3-Di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranos-
yl)-(1→4)-[2,3-di-O-methyl-6-O-(2-naphthyl)methyl-α-L-idopyr-
anosyl]-(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (20): To a
solution of compound 14 (90 mg, 0.113 mmol) and compound696
17[31] (98 mg, 0.181 mmol, 1.6 equiv.) in dry CH2Cl2 (1320 μL) 4 Å
molecular sieves (80 mg) were added. After stirring at room temper-
ature for 30 min, the mixture was cooled to –40 °C and solutions
of NIS (61 mg, 0.272 mmol, 1.5 equiv.) in dry THF (84 μL) and AgOTf
(11 mg, 0.043 mmol, 0.24 equiv.) in dry toluene (84 μL) were added.701
After stirring at –40 °C to –20 °C for 4 h, TLC analysis (7:3 n-hexane/
EtOAc) showed complete consumption of the donor. The reaction
mixture was neutralized with Et3N (200 μL), diluted with CH2Cl2
(100 mL), and filtered. The filtrate was washed with an aqueous
solution of Na2S2O3 (10 %, 20 mL), a saturated aqueous solution of706
NaHCO3 (2 × 20 mL), and water (2 × 20 mL), dried, and concen-
trated. The crude product was purified by column chromatography
on silica gel (65:35 n-hexane/EtOAc) to give compound 20 (111 mg,
80 %) as a colorless syrup. [α]D25 = +11.0 (c = 0.10, CHCl3); Rf 0.50
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(6:4 n-hexane/EtOAc). 1H NMR (CDCl3, 500 MHz): δ = 7.72–7.19 (m, 711
37 H, arom), 5.52 (s, 1 H, Hac), 5.25 (d, J = 3.8 Hz, 1 H, H-1′′), 4.98
(d, J = 6.9 Hz, 1 H, H-1′), 4.98–4.60 (m, 8 H, 4 × Bn-CH2), 4.58 (d, J =
4.0 Hz, 1 H, H-1), 4.48–4.38 (m, 4 H, NAP-CH2, Bn-CH2), 4.15 (dd, J =
4.7, J = 10.1 Hz, 1 H, H-6′′a), 4.04 (dd, J = 4.6 H, J = 9.5 Hz, 1 H, H-
5′), 3.93–3.88 (m, 4 H, H-3, H-3′′, H-4, H-4′), 3.79–3.74 (m, 5 H, H-3′, 716
H-5, H-5′′, H-6a, H-6′a), 3.71–3.64 (m, 3 H, H-6b, H-6′b, H-6′′b), 3.60
(t, J = 9.4 Hz, 1 H, H-4′′), 3.58 (dd, J = 3.8, J = 9.4 Hz, 1 H, H-2′′),
3.52 (s, 3 H, C-3′-OCH3), 3.50–3.47 (m, 1 H, H-2), 3.49 (s, 3 H, C-2′-
OCH3), 3.36 (s, 3 H, C-1-OCH3), 3.05 (t, J = 7.4 Hz, 1 H, H-2′) ppm.
13C NMR (CDCl3, 125 MHz): δ = 139.4, 138.8, 138.5, 138.3, 137.5, 721
135.8, 133.3, 132.8 (9C, 9 × Cq arom), 129.9–125.6 (37C, arom), 101.2
(1C, Cac), 100.0 (1C, C-1′), 99.1 (1C, C-1′′), 98.4 (1C, C-1), 84.8 (1C, C-
2′), 82.5 (1C, C-3′), 82.3 (1C, C-4′′), 80.2 (1C, C-3), 79.4 (1C, C-2), 79.0
(1C, C-2′′), 78.3 (1C, C-4′), 76.6 (1C, C-4), 76.3 (1C, C-3′′), 75.3, 75.0,
73.6, 73.2 (6C, NAP-CH2, 5 × Bn-CH2), 72.2 (1C, C-5′), 70.4 (1C, C-5), 726
69.1 (1C, C-6′), 68.9 (1C, C-6′′), 68.3 (1C, C-6), 63.3 (1C, C-5′′), 60.4,
60.3 (2C, 2 × OCH3), 55.3 (1C, C-1-OCH3) ppm. MS (ESI-TOF): m/z
calcd. for C74H80NaO16: 1247.5339 [M + Na]+, found 1247.5331.
Methyl (2,3,6-Tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-[2,3-di-
O-methyl-6-O-(2-naphthyl)methyl-α-L-idopyranosyl]-(1→4)- 731
2,3,6-tri-O-benzyl-α-D-glucopyranoside (21a) and Methyl (2,3,4-
Tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-[2,3-di-O-methyl-6-O-
(2-naphthyl)methyl-α-L-idopyranosyl]-(1→4)-2,3,6-tri-O-benzyl-
α-D-glucopyranoside (21b): To a solution of 20 (95 mg,
0.077 mmol) in dry THF (235 μL) 4 Å MS (60 mg) and Me3N·BH3 736
(34 mg, 0.465 mmol, 6 equiv.) were added and the reaction mixture
was stirred for 30 min at room temperature. After 30 min AlCl3
(62 mg, 0.465 mmol, 6 equiv.) was added and the mixture was
stirred at room temperature for 2 h. After 2 h the reaction mixture
was diluted with CH2Cl2 (50 mL), and washed with H2O (2 × 15 mL). 741
The organic layer was dried with MgSO4 and concentrated. The
crude product was purified by silica gel chromatography (6:4 n-
hexane/EtOAc) to give 21a (66 mg, 70 %) as a colorless syrup and
21b (18 mg, 19 %) as a colorless syrup.
Data of 21a: [α]D25 = +26.7 (c = 0.12, CHCl3); Rf 0.66 (1:1 n-hexane/ 746
EtOAc). 1H NMR (CDCl3, 500 MHz): δ = 7.74–7.16 (m, 37 H, arom),
5.27 (d, J = 3.5 Hz, 1 H, H-1′′), 4.98 (d, J = 7.4 Hz, 1 H, H-1′), 4.96–
4.60 (m, 8 H, 4 × Bn-CH2), 4.58 (d, J = 4.3 Hz, 1 H, H-1), 4.49–4.36
(m, 6 H, NAP-CH2, 2 × Bn-CH2), 4.10 (dd, J = 4.8, J = 9.8 Hz, 1 H, H-
5′), 3.94–3.86 (m, 3 H, H-3, H-4, H-4′), 3.80 (dd, J = 3.7, J = 10.7 Hz, 751
1 H, H-6a), 3.77–3.73 (m, 3 H, H-3′, H-5, H-6′a), 3.69–3.60 (m, 5 H,
H-3′′, H-4′′, H-5′′, H-6b, H-6′b), 3.55–3.50 (m, 2 H, H-2′′, H-6′′a), 3.51
(s, 3 H, C-3′-OCH3), 3.49–3.44 (m, 2 H, H-2, H-6′′b), 3.47 (s, 3 H, C-2′-
OCH3), 3.36 (s, 3 H, C-1-OCH3), 3.06 (t, J = 7.3 Hz, 1 H, H-2′), 2.23 (s,
1 H, C-4′′-OH) ppm. 13C NMR (CDCl3, 125 MHz): δ = 139.4, 138.8, 756
138.6, 138.4, 138.0, 135.9, 133.4, 132.9 (9C, 9 × Cq arom), 128.6–
125.8 (37C, arom), 100.0 (1C, C-1′), 98.4 (1C, C-1), 98.0 (1C, C-1′′),
84.5 (1C, C-2′), 82.2 (1C, C-3′), 80.9 (1C, C-3′′), 80.3 (1C, C-3), 79.5
(1C, C-2), 79.3 (1C, C-2′′), 76.6 (1C, C-4), 76.0 (1C, C-4′), 75.5, 75.2,
73.7, 73.6, 73.3, 72.4 (7C, NAP-CH2, 6 × Bn-CH2), 71.9 (1C, C-5′), 70.9, 761
70.8 (2C, C-4′′, C-5′′), 70.5 (1C, C-5), 69.4 (1C, C-6′), 69.2 (1C, C-6′′),
68.4 (1C, C-6), 60.3, 60.2 (2C, 2 × OCH3), 55.4 (1C, C-1-OCH3) ppm.
MS (ESI-TOF): m/z calcd. for C74H82NaO16: 1249.5495 [M + Na]+,
found 1249.5487.
Data of 21b: [α]D25 = +31.8 (c = 2.70, CHCl3); Rf 0.46 (1:1 n-hexane/ 766
EtOAc). 1H NMR (CDCl3, 500 MHz): δ = 7.72–7.19 (m, 37 H, arom),
5.24 (d, J = 3.6 Hz, 1 H, H-1′′), 4.97 (d, J = 10.8 Hz, 1 H, Bn-CH2a),
4.98 (d, J = 6.9 Hz, 1 H, H-1′), 4.89–4.69 (m, 7 H, Bn-CH2b, 3 × Bn-
CH2), 4.60–4.58 (m, 2 H, Bn-CH2), 4.57 (d, J = 4.6 Hz, 1 H, H-1), 4.49–
4.36 (m, 4 H, NAP-CH2, Bn-CH2), 4.06 (dd, J = 4.6, J = 9.6 Hz, 1 H, H- 771
5′), 3.93–3.84 (m, 4 H, H-3, H-3′′, H-4, H-4′), 3.79 (dd, J = 3.7, J =
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10.7 Hz, 1 H, H-6a), 3.76–3.72 (m, 3 H, H-3′, H-5, H-6′a), 3.69–3.66
(m, 2 H, H-6b, H-6′b), 3.60–3.55 (m, 3 H, H-5′′, H-6′′a,b), 3.52–3.46
(m, 3 H, H-2, H-2′′, H-4′′), 3.51 (s, 3 H, C-3′-OCH3), 3.48 (s, 3 H, C-2′-
OCH3), 3.37 (s, 3 H, C-1-OCH3), 3.05 (t, J = 7.3 Hz, 1 H, H-2′), 1.70 (s,776
1 H, C-6′′-OH) ppm. 13C NMR (CDCl3, 125 MHz): δ = 139.4, 138.8,
138.6, 138.4, 138.3, 135.9, 133.4, 132.9 (9C, 9 × Cq arom), 128.6–
125.7 (37C, arom), 100.1 (1C, C-1′), 98.5 (1C, C-1), 98.0 (1C, C-1′′),
84.7 (1C, C-2′), 82.5 (1C, C-3′), 81.7 (1C, C-3′′), 80.3 (1C, C-3), 79.9
(1C, C-2′′), 79.5 (1C, C-2), 77.3 (1C, C-4′′), 76.7 (1C, C-4), 76.1 (1C, C-781
4′), 75.5, 75.4, 75.2, 73.7, 73.3, 72.8 (7C, NAP-CH2, 6 × Bn-CH2), 72.0
(1C, C-5′), 71.7 (1C, C-5′′), 70.5 (1C, C-5), 69.2 (1C, C-6′), 68.4 (1C, C-
6), 61.7 (1C, C-6′′), 60.4 (2C, 2 × OCH3), 55.4 (1C, C-1-OCH3) ppm. MS
(ESI-TOF): m/z calcd. for C74H82NaO16: 1249.5495 [M + Na]+, found
1249.5483.786
Methyl (6-O-Benzyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl)-
(1→4)-[2,3-di-O-acetyl-6-O-(2-naphthyl)methyl--D-glucopyran-
osyl]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-(6-
O-tert-butyldiphenylsilyl-2,3-di-O-methyl-α-L-idopyranosyl)-
(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (23) and Methyl791
(6-O-Benzyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl)-(1→4)-[2,3-
di-O-acetyl-6-O-(2-naphthyl)methyl--D-glucopyranosyl]-(1→4)-
2,3,6-tri-O-benzyl-α-D-glucopyranoside (24): To a solution of tri-
saccharide acceptor 19a (32 mg, 0.024 mmol) and disaccharide do-
nor 22[32] (28.6 mg, 0.036 mmol, 1.5 equiv.) in dry CH2Cl2 (1.2 mL)796
4 Å MS (150 mg) were added and the reaction mixture was stirred
at room temperature. After 30 min the stirred mixture was cooled
to –20 °C under argon. After at this temperature, NIS (12 mg,
0.054 mmol, 1.5 equiv. to the donor) was dissolved in dry THF
(30 μL) and AgOTf (2 mg, 0.009 mmol, 0.24 equiv. to the donor)801
dissolved in dry toluene (30 μL) were added. The temperature was
warmed up to +5 °C and the reaction mixture was stirred for 4 h.
After 4 h the reaction mixture was quenched with Et3N (150 μL),
diluted with CH2Cl2 (25 mL), filtered and the mixture was washed
with saturated aqueous solution of Na2S2O3 (2 × 5 mL), saturated806
aqueous solution of NaHCO3 (5 mL) and with H2O (2 × 5 mL) until
neutral pH. The organic layer was dried on MgSO4 and concen-
trated. The crude product was purified by silica gel chromatography
(6:4 n-hexane/EtOAc to 1:1 n-hexane/EtOAc) to give 23 (5 mg, 11 %)
as a colorless syrup and 24 (22 mg, 46 %) as a colorless syrup.811
Data of 23: [α]D25 = +27.0 (c = 0.10, CHCl3); Rf 0.48 (1:1 n-hexane/
EtOAc). 1H NMR (CDCl3, 500 MHz): δ = 7.80–7.10 (m, 52 H, arom),
5.27 (d, J = 3.8 Hz, 1 H, H-1′′), 5.12–4.25 (m, 22 H, 7 × Bn-CH2, NAP-
CH2, 4 × H-1, H-2-E, H-3-E), 3.96–2.98 (m, 46 H, 6 × OCH3, 28 skele-
ton hydrogen), 2.02, 1.95 (2 × s, 6 H, 2 × Ac-CH3), 1.03 (s, 9 H,816
tBu-CH3) ppm. 13C NMR (CDCl3, 125 MHz): δ = 148.7, 147.5, 144.8,
143.8, 143.5, 139.5, 138.3, 137.6, 133.3, 133.2, 132.9, 132.8 (12C, 12 ×
Cq arom), 135.7–125.6 (52C, arom), 101.1, 100.0, 98.9, 98.2, 98.0 (5C,
5 × C-1), 85.0, 83.4, 82.0, 80.6, 80.4, 79.4, 79.2, 76.8, 75.6, 75.3, 75.2,
73.0, 71.4, 71.1, 69.0, 68.5, 67.7 (20C, skeleton carbons), 75.1, 73.5,821
73.1 (9C, 7 × Bn-CH2, 2 × NAP-CH2), 70.9, 70.8, 70.7 (3C, C-5, C-5′,
C-5′′), 67.7, 68.5, 68.7, 69.0 (4C, 4 × C-6), 63.2 (1C, C-6-G), 60.9, 60.5,
59.4 (5C, 5 × OCH3), 55.4 (1C, C-1-OCH3), 21.2, 20.9 (2C, 2 × Ac-CH3),
27.1 (3C, 3 × tBu-CH3), 19.2 (1C, Cq tBu) ppm. MS (MALDI-TOF): m/z
calcd. for C116H136NaO28Si: 2027.888 [M + Na]+, found 2027.809.826
Data of 24: [α]D25 = +25.8 (c = 0.12, CHCl3); Rf 0.35 (1:1 n-hexane/
EtOAc). 1H NMR (CDCl3, 500 MHz): δ = 7.81–7.13 (m, 27 H, arom),
5.11 (t, J = 9.1 Hz, 1 H, H-3′), 5.07 (d, J = 3.5 Hz, 1 H, H-1′′), 5.02 (d,
J = 11.6 Hz, 1 H, Bn-CH2a), 4.85 (dd, J = 9.4 Hz, J = 8.2 Hz, 1 H,
H-2′), 4.77–4.58 (m, 5 H, Bn-CH2b, 2 × Bn-CH2), 4.56–4.52 (m, 2 H, H-831
1, H-1′), 4.48–4.27 (m, 4 H, NAP-CH2, Bn-CH2), 3.92 (t, J = 9.2 Hz, 1
H, H-4′), 3.90–3.85 (m, 2 H, H-3, H-4), 3.75 (dd, J = 10.7, J = 3.2 Hz,
1 H, H-6a), 3.69–3.60 (m, 5 H, H-5, H-5′′, H-6b, H-6′a,b), 3.58 (s, 3 H,
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C-3′-OCH3), 3.44 (dd, J = 10.1, J = 3.3 Hz, 1 H, H-6′′a), 3.42–3.37 (m,
3 H, H-2, H-3′′, H-6′′b), 3.41, 3.40 (2 × s, 6 H, C-4′′-OCH3, C-2′′-OCH3), 836
3.34 (s, 3 H, C-1-OCH3), 3.23–3.21 (m, 1 H, H-5′), 3.17 (t, J = 9.5 Hz,
1 H, H-4′′), 3.05 (dd, J = 9.8, J = 3.5 Hz, 1 H, H-2′′), 2.01, 1.94 (2 × s,
6 H, 2 Ac-CH3) ppm. 13C NMR (CDCl3, 125 MHz): δ = 170.1, 169.8
(2C, 2 × Cq Ac), 139.6, 138.4, 138.2, 137.8, 136.2, 133.4, 133.0 (7C,
7 × Cq arom), 128.8–125.8 (27C, arom), 100.0 (1C, C-1′), 98.5 (1C, C- 841
1), 97.9 (1C, C-1′′), 83.3 (1C, C-3′′), 81.9 (1C, C-2′′), 80.3 (1C, C-3),
79.4 (1C, C-4′′), 79.3 (1C, C-2), 77.1 (1C, C-4), 75.3 (1C, C-3′), 75.2 (1C,
C-5′), 75.0 (1C, C-4′), 74.0, 73.8, 73.4 (5C, 4 × Bn-CH2, NAP-CH2), 73.0
(1C, C-2′), 71.3 (1C, C-5′′), 70.0 (1C, C-5), 68.8 (1C, C-6′), 68.5 (1C, C-
6′′), 67.9 (1C, C-6), 60.8 (1C, C-3′′-OCH3), 60.5 (1C, C-4′′-OCH3), 59.4 846
(1C, C-2′′-OCH3), 55.4 (1C, C-1-OCH3), 21.2, 20.9 (2C, 2 × Ac-CH3)
ppm. MS (ESI-TOF):m/z calcd. for C65H76NaO18: 1167.4924 [M + Na]+,
found 1167.4885.
Methyl (6-O-Benzyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl)-
(1→4)-[2,3-di-O-acetyl-6-O-(2-naphthyl)methyl--D-glucopyran- 851
osyl]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-[2,3-
di-O-methyl-6-O-(2-naphthyl)methyl-α-L-idopyranosyl]-(1→4)-
2,3,6-tri-O-benzyl-α-D-glucopyranoside (25): To a solution of tri-
saccharide acceptor 21a (38 mg, 0.031 mmol) and disaccharide do-
nor 22[32] (37 mg, 0.047 mmol, 1.5 equiv.) in dry CH2Cl2 (1.2 mL) 856
4 Å MS (250 mg) were added and the reaction mixture was stirred
at room temperature. After 30 min the stirred mixture was cooled
to –20 °C under argon. After at this temperature, NIS (16 mg,
0.070 mmol, 1.5 equiv. to the donor) and TfOH (2.0 μL, 0.020 mmol,
0.3 equiv. to the NIS) dissolved in dry THF (28 μL) were added. The 861
temperature was warmed up to +5 °C and the reaction mixture was
stirred for 4 h. Than reaction mixture was quenched with Et3N
(150 μL), diluted with CH2Cl2 (25 mL), filtered and the mixture was
washed with saturated aqueous solution of Na2S2O3 (2 × 5 mL),
saturated aqueous solution of NaHCO3 (5 mL) and H2O (2 × 5 mL) 866
until neutral pH. The organic layer was dried on MgSO4 and concen-
trated. The crude product was purified by silica gel chromatography
(55:45 n-hexane/EtOAc to 1:1 n-hexane/EtOAc) to give 25 (41 mg,
70 %) as a colorless syrup. [α]D25 = +60.0 (c = 0.10, CHCl3); Rf 0.45
(1:1 n-hexane/EtOAc). 1H NMR (CDCl3, 500 MHz): δ = 7.77–7.07 (m, 871
49 H, arom), 5.22 (d, J = 3.7 Hz, 1 H, H-1-F), 5.09–5.05 (m, 2 H, H-1-
D, H-3-E), 4.97–4.95 (m, 2 H, 2 × Bn-CH2a), 4.89 (d, J = 6.9 Hz, 1 H,
H-1-G), 4.82 (t, J = 8.3 Hz, 1 H, H-2-E), 4.80–4.25 (m, 18 H, H-1-H, H-
1-E, 2 × NAP-CH2, 2 × Bn-CH2b, 5 × Bn-CH2), 4.05 (dd, J = 5.0, J =
9.7 Hz, 1 H, H-5-G), 3.95–3.84 (m, 5 H, H-3-H, H-4-E, H-4-F, H-4-G, H- 876
4-H), 3.79–3.68 (m, 7 H, H-3-F, H-5-F, H-5-H, H-6a-F, H-6a-G, H-6a,b-
H), 3.67–3.61 (m, 4 H, H-3-G, H-6b-G, H-6a,b-E), 3.60–3.55 (m, 4 H,
H-5-D, C-3-D-OCH3), 3.50–3.44 (m, 10 H, H-2-F, H-2-H, H-6b-F, H-6a-
D, C-2-G-OCH3, C-3-G-OCH3), 3.43–3.39 (m, 8 H, H-3-D, H-6b-D, C-2-
D-OCH3, C-3-D-OCH3), 3.34 (s, 3 H, C-1-H-OCH3), 3.20–3.15 (m, 2 H, 881
H-4-D, H-5-E), 3.06–3.00 (m, 2 H, C-2-D, H-2-G), 2.00, 1.82 (2 × s, 6
H, 2 × Ac-CH3) ppm. 13C NMR (CDCl3, 125 MHz): δ = 170.1, 169.7
(2C, 2 × Ac-CH3), 139.6, 139.5, 138.6, 138.5, 138.3, 138.2, 137.7,
136.2, 135.9, 133.4, 133.9 (13C, 13 × Cq arom), 128.9–125.8 (49C,
arom), 100.0 (1C, C-1-E), 99.8 (1C, C-1-G), 98.6 (1C, C-1-F), 98.4 (1C, 886
C-1-H), 97.9 (1C, C-1-D), 84.5 (1C, C-2-G), 83.3 (1C, C-3-D), 82.2 (1C,
C-3-G), 81.9 (1C, C-2-D), 80.3 (1C, C-3-H), 80.0 (1C, C-3-F), 79.5 (1C,
C-2-H), 79.4 (1C, C-4-D), 79.0 (1C, C-2-F), 76.8 (1C, C-4-F), 76.6 (1C,
C-4-H), 76.5 (1C, C-4-G), 75.5 (1C, NAP-CH2), 75.3, (1C, C-3-E), 75.2
(1C, C-5-E), 75.0 (1C, NAP-CH2), 74.9 (1C, C-4-E), 73.8, 73.7, 73.4, 73.3, 891
73.1 (7C, 7 × Bn-CH2), 72.9 (1C, C-2-E), 72.2 (1C, C-5-G), 71.3 (1C, C-
5-D), 71.0 (1C, C-5-F), 70.5 (1C, C-5-H), 68.9 (1C, C-6-G), 68.8 (1C, C-
6-E), 68.5 (1C, C-6-D), 68.3 (1C, C-6-H), 67.6 (1C, C-6-F), 60.8 (1C, C-
3-D-OCH3), 60.5 (2C, C-3-G-OCH3, C-4-D-OCH3), 60.3 (1C, C-2-G-
OCH3), 59.3 (1C, C-2-D-OCH3), 55.4 (1C, C-1-H-OCH3), 21.1, 20.8 (2C, 896
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2 × Ac-CH3) ppm. MS (MALDI-TOF): m/z calcd. for C111H126NaO28:
1931.190 [M + Na]+, found 1931.124.
Methyl (6-O-Benzyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl)-
(1→4)-[6-O-(2-naphthyl)methyl--D-glucopyranosyl]-(1→4)-
(2,3,6-tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-[2,3-di-O-901
methyl-6-O-(2-naphthyl)methyl-α-L-idopyranosyl]-(1→4)-2,3,6-
tri-O-benzyl-α-D-glucopyranoside (26): Compound 25 (33 mg,
0.017 mmol) was dissolved in MeOH (1.0 mL) and NaOMe was
added (5 mg, 0.092 mmol, pH ≈ 10) and the reaction mixture was
stirred at room temperature for 24 h. Than the reaction mixture was906
neutralized by Amberlite IR-120 (H+) ion-exchange resin, filtered,
washed with MeOH and concentrated. The crude product was puri-
fied by column chromatography (65:35 = n-hexane/acetone) to give
26 (25 mg, 78 %) as a colorless syrup. [α]D25 = +55.0 (c = 0.06, CHCl3);
Rf 0.29 (7:3 n-hexane/acetone). 1H NMR (CDCl3, 500 MHz): δ = 7.77–911
7.13 (m, 49 H, arom), 5.22 (d, J = 3.7 Hz, 1 H, H-1-F), 5.03 (d, J =
3.5 Hz, 1 H, H-1-D), 4.96 (d, J = 5.9 Hz, 1 H, H-1-G), 4.95–4.28 (m, 20
H, H-1-H, H-1-E, 2 × NAP-CH2, 7 × Bn-CH2), 4.00–3.96 (m, 2 H, H-4-F,
H-5-G), 3.90–3.82 (m, 3 H, H-3-F, H-4-G, H-6a-F), 3.79–3.65 (m, 9 H,
H-3-H, H-3-G, H-4-H, H-5-H, H-5-F, H-6a,b-H, H-6a,b-G), 3.61 (s, 3 H,916
C-3-D-OCH3), 3.59–3.57 (m, 1 H, H-5-D), 3.56 (s, 3 H, C-2-D-OCH3),
3.54–3.50 (m, 2 H, H-3-E-OH, H-6a-E), 3.48 (s, 4 H, H-2-F, C-3-G-OCH3),
3.47–3.40 (m, 13 H, H-2-H, H-3-D, H-3-E, H-4-E, H-6a-D, H-6b-F, H-
6b-E, C-2-G-OCH3, C-4-D-OCH3), 3.36 (s, 3 H, C-1-H-OCH3), 3.33–3.29
(m, 2 H, H-2-E, H-6b-D), 3.22 (s, 1 H, C-2-E-OH), 3.19–3.13 (m, 3 H,921
H-2-D, H-4-D, H-5-E), 3.05–3.02 (m, 1 H, H-2-G) ppm. 13C NMR (CDCl3,
125 MHz): δ = 139.5, 138.6, 138.4, 138.1, 137.7, 136.4, 136.0, 133.4,
133.0, 132.9 (13C, 13 × Cq arom), 128.6–125.8 (49C, arom), 103.1 (1C,
C-1-E), 100.6 (1C, C-1-D), 100.0 (1C, C-1-G), 98.5 (1C, C-1-H), 98.3 (1C,
C-1-F), 84.7 (1C, C-2-G), 84.1 (1C, C-3-D), 82.9 (1C, C-2-D), 82.5 (1C,926
C-3-G), 82.0 (1C, C-4-E), 80.6 (1C, C-3-F), 80.3 (1C, C-3-H), 79.5 (2C,
C-2-H, C-4-D), 79.4 (1C, C-2-F), 76.7 (2C, C-4-F, C-4-H), 76.3 (1C, C-4-
G), 76.1 (1C, C-3-E), 75.3, 74.8 (2C, 2 × NAP-CH2), 74.7, (1C, C-5-E),
74.0 (1C, C-2-E), 73.7, 73.6, 73.4, 73.3, 72.9 (7C, 7 × Bn-CH2), 72.0
(1C, C-5-G), 71.4 (1C, C-5-D), 70.8 (1C, C-5-F), 70.5 (1C, C-5-H), 69.3931
(1C, C-6-G), 69.0 (1C, C-6-E), 68.5 (2C, C-6-D, C-6-H), 68.3 (1C, C-6-F),
60.9 (1C, C-3-D-OCH3), 60.6 (1C, C-4-D-OCH3), 60.3 (3C, C-2-G-OCH3,
C-3-G-OCH3, C-2-D-OCH3), 55.4 (1C, C-1-H-OCH3) ppm. MS (MALDI-
TOF): m/z calcd. for C107H122NaO26: 1845.812 [M + Na]+, found
1845.714.936
Methyl (6-O-Benzyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl)-
(1→4)-[2,3-di-O-methyl-6-O-(2-naphthyl)methyl--D-glucopyr-
anosyl]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-
[2,3-di-O-methyl-6-O-(2-naphthyl)methyl-α-L-idopyranosyl]-
(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (27): To a solution941
of 26 (21 mg, 0.0115 mmol) in dry DMF (250 μL) was added NaH
(60 %, 10 mg, 0.250 mmol) at 0 °C. After stirring for 30 min at 0 °C,
MeI (20 μL, 0.321 mmol) was added and stirred for 24 h at room
temperature. When complete conversion of the starting material
into a main spot had been observed by TLC analysis, CH3OH946
(500 μL) was added. The reaction mixture was stirred for 5 min and
the solvents were evaporated. The residue was dissolved in CH2Cl2
(25 mL), and washed with H2O (2 × 5.0 mL), the organic layer was
filtered, dried and the solvents evaporated. The crude product was
purified by silica gel chromatography (6:4 = n-hexane/acetone) to951
give 27 (16 mg, 80 %) as a colorless syrup. [α]D25 = +45.7 (c = 0.07,
CHCl3); Rf 0.58 (6:4 n-hexane/acetone). 1H NMR (CDCl3, 500 MHz):
δ = 7.78–7.08 (m, 49 H, arom), 5.58 (d, J = 3.7 Hz, 1 H), 5.23 (d, J =
3.6 Hz, 1 H), 5.02–4.06 (m, 21 H, 3 × H-1, 7 × Bn-CH2, 2 × NAP-CH2),
4.06 (dd, J = 4.7, J = 9.6 Hz, 1 H), 3.98 (t, J = 9.4 Hz, 1 H), 3.89–3.62956
(m, 17 H), 3.62–3.32 (m, 4 H), 3.60, 3.54, 3.48, 3.45, 3.38, 3.36, 3.33
(7 × s, 24 H, 8 × OCH3), 3.29–3.21 (m, 4 H), 3.15 (dd, J = 3.7, J =
9.8 Hz, 1 H), 3.04–3.00 (m, 1 H), 2.94–2.91 (m, 1 H) ppm. 13C NMR
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(CDCl3, 125 MHz): δ = 139.7, 139.4, 138.6, 138.4, 138.2, 138.0, 136.5,
135.9, 133.4, 133.0, 132.9 (13C, 13 × Cq arom), 128.7–125.7 (49C, 961
arom), 102.9, 100.0, 98.5, 96.3 (5C, 5 × C-1), 86.7, 84.7, 84.6, 83.6,
82.4, 81.9, 80.4, 79.9, 79.5, 79.4, 79.0, 77.0, 76.7, 76.2, 74.8, 72.4, 72.2,
71.4, 70.9, 70.5 (20C skeleton carbons), 75.6, 74.9, 73.8, 73.5, 73.4,
73.3, 73.2 (9C, 2 × NAP-CH2, 7 × Bn-CH2), 69.4, 68.3, 68.2, 67.8 (5C,
5 × C-6), 60.9, 60.5, 60.3, 59.8, 59.6 (7C, 7 × OCH3), 55.4 (1C, C-1-H- 966
OCH3) ppm. MS (MALDI-TOF): m/z calcd. for C109H126NaO26:
1873.843 [M + Na]+, found 1873.749.
Methyl (6-O-Benzyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl)-
(1→4)-(2,3-di-O-methyl--D-glucopyranosyl)-(1→4)-(2,3,6-tri-O-
benzyl-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L-idopyr- 971
anosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (28): To a
vigorously stirred solution of 27 (14 mg, 0.007 mmol) in CH2Cl2
(2.0 mL) and H2O (250 μL), DDQ (5.0 mg, 0.021 mmol) was added.
After 30 min the mixture was diluted with CH2Cl2 (20 mL) and ex-
tracted with saturated aqueous NaHCO3 (2 × 5 mL) and H2O (2 × 976
5 mL), dried and concentrated. The crude product was purified by
silica gel chromatography (6:4 n-hexane/acetone) to give 28 (8 mg,
71 %) as a colorless syrup. [α]D25 = +61.4 (c = 0.08, CH2Cl2); Rf 0.52
(6:4 n-hexane/acetone). 1H NMR (CDCl3, 360 MHz): δ = 7.39–7.18
(m, 35 H, arom), 5.52 (d, J = 3.7 Hz, 1 H), 5.15 (d, J = 3.4 Hz, 1 H), 981
4.93–4.50 (m, 16 H, 7 × Bn-CH2, 2 × H-1), 4.28 (d, J = 7.8 Hz, 1 H),
3.93–3.63 (m, 15 H), 3.62–3.15 (m, 12 H), 3.61, 3.58, 3.54, 3.49, 3.44,
3.42, 3.39, 3.35 (8 × s, 24 H, 8 × OCH3), 3.03–2.94 (m, 3 H), 2.36, 2.08
(2 × s, 2 H, 2 × OH) ppm. 13C NMR (CDCl3, 90 MHz): δ = 138.7, 138.4,
138.0, 137.8, 137.7, 137.5, 137.4 (7C, 7 × Cq arom), 128.2–127.3 (35C, 986
arom), 102.3, 98.6, 97.8, 97.0, 96.3 (5C, 5 × C-1), 86.1, 84.4, 83.1, 82.6,
81.5, 81.4, 80.1, 79.6, 79.2, 78.4, 75.2, 74.1, 73.9, 71.2, 70.8, 70.6, 70.1
(20C, skeleton carbons), 75.5, 74.9, 73.2, 73.1, 72.7 (7C, 7 × Bn-CH2),
68.1, 68.0, 67.4, 61.6 (5C, 5 × C-6), 60.4, 60.1, 60.0, 59.6, 59.4, 59.3,
59.2 (7C, 7 × OCH3), 54.9 (C-1-H-OCH3) ppm. MS (ESI-TOF): m/z calcd. 991
for C87H110NaO26: 1593.7178 [M + Na]+, found 1593.7163.
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Short Synthesis of Idraparinux by
Applying a 2-O-Methyl-4,6-O-aryl-
methylene Thioidoside as a 1,2-1076
trans-α-Selective Glycosyl Donor
Our new route to idraparinux is based donor building block. The assembly of
on a short and straightforward synthe- idraparinux was achieved by an F+GH
sis of a 4,6-cyclic-acetal-protected L- and DE+FGH coupling sequence with
idosyl thioglycoside bearing a C2-non-1081 full stereoselectivity in each glycosyl-
participating group, which can be ation step.
used directly as an α-selective glycosyl
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